Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — H1 2025 Earnings Presentation
26 slides from Faron Pharmaceuticals Oy's earnings presentation, Aug 27, 2025
Slide 1: Significant clinical and financial milestones achieved in first half of 2025
Significant clinical and financial milestones achieved in first half of 2025 Faron Pharmaceuticals Half-Year Report, January–June 2025 1 27-AUG-2025 HALF-YEAR REPORT, JANUARY-JUNE 2025
Slide 2: Corporate Disclaimer
Corporate Disclaimer The contents of this presentation have not been approved by an authorized person within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). Reliance on the contents of this presentation for the purpose of engaging in any investment act
Slide 3: H1 Results Agenda and Presenters
H1 Results Agenda and Presenters Positive clinical and financial milestones mark strong first half Dr. Juho Jalkanen, CEO, Faron Clinical & regulatory update Dr. Petri Bono, CMO, Faron Outlook and Q&A session Financial Results, 1 January to 30 June 2025 Yrjö Wichmann, CFO, Faron 3 27-AUG-2025 HALF-Y
Slide 4: First drug to tackle the core biology of high-risk myelodysplastic syndrome
First drug to tackle the core biology of high-risk myelodysplastic syndrome ▪ Higher-risk myelodysplastic syndrome (HR MDS) is one of the deadliest of all cancers with no new treatments for 20 years ▪ Bexmarilimab is a first-in-class anti-CLEVER-1, a master immunosuppressive receptor on myeloid cell
Slide 5: Bexmarilimab – Mode of Action
Bexmarilimab – Mode of Action The first drug to tackle the core biology of HR MDS 1 Bexmarilimab deactivates the energy production of CLEVER-1 is an immunosuppressive receptor on macrophages immune cells, responsible for 3 the cancer cells, enabling existing therapies. (ie. AZA), eliminating infecte
Slide 6: Induction of hematopoiesis in the bone marrow of BEXMAB trial patients
Induction of hematopoiesis in the bone marrow of BEXMAB trial patients Eo-Baso-Mast Precursor CXCL8hi Erythroid Precursor TGFB1hi MPP-MkEry/MEP PPARG+ LGALS2+ S100A12hi 6 27-AUG-2025 HALF-YEAR REPORT, JANUARY-JUNE 2025
Slide 7: Benefits of targeting Clever-1 in myeloid malignancies
Benefits of targeting Clever-1 in myeloid malignancies 1. Immune activation via monocytes/macrophages – antigen presentation and T cell activation 2. Apoptotic priming of blasts via impaired mitochondrial metabolism – blast cell sensitization to SoC 3. Increased hematopoiesis by targeting progenitor
Slide 8: Why give another myelosuppressive and toxic drug to already frail and deeply cytopenic patients?
Why give another myelosuppressive and toxic drug to already frail and deeply cytopenic patients? Bex has an improved safety profile with potential for hematological recovery Bcl2: 43%-88% CD47: 36% Failed Assets TIM3: 62% Bcl2: 19%-71% Bexmarilimab CD47: 30%-79% Bcl2: 19%-65% Bcl2: 10%-65% CD47: 46%
Slide 9: Faron's H1 2025 Clinical & regulatory update
Faron’s H1 2025 Clinical & regulatory update Dr. Petri Bono CMO, Faron 9 27-AUG-2025 HALF-YEAR REPORT, JANUARY-JUNE 2025
Slide 10: Responses continue to deepen as the bone marrow recovers in frontline HR MDS
Responses continue to deepen as the bone marrow recovers in frontline HR MDS BEXMAB Frontline HR MDS August’25 Data-cut, CR increases from 28% to 43% n (%) Total Pt N=21 IWG 2006 CR 9 (43%) PR 1 (5%) mCR 5 (24%) HI 2 (10%) SD 2 (10%) No Response / 2 (10%) Progressive Disease ORR (% of evaluable, 81%
Slide 11: Positive BEXMAB end of Phase II meeting with FDA
Positive BEXMAB end of Phase II meeting with FDA 1. Clear Path to Registration FDA supports moving into a seamless Phase 2/3 trial design, enabling dose optimization (comparing 1 & 3 mg/kg to placebo) and registrational study start in frontline HR MDS in Q2 2026. 2. Frontline accelerated approval po
Slide 12: Registrational study plan for HR MDS per FDA
Registrational study plan for HR MDS per FDA Seamless adaptive phase II/III with accelerated approval and re-sizing improves likelihood of success 2026 2027 2028 2029 2030 2031 H1 PHASE H2 II/III H1 H2 H1 H2 H1 PHASE H2 III & BLA H1 H2 H1 H2 Bexmarilimab 3mg/kg + azacitidine (n=40) FRONTLINE HR MDS
Slide 13: Newly revised 2023 MDS response criteria will be used in bexmarilimab Phase III trial
Newly revised 2023 MDS response criteria will be used in bexmarilimab Phase III trial improving likelihood of success IWG 2006 IWG 2023 CR CReq CR CReq Screening - BM Blasts Not specified - Screening - BM Blasts ≥ 5% < 5% < 5% and complete Response – BM Blasts ≤ 5% blasts Response – BM Blasts < 5% b
Slide 14: Financial Results January to June 2025
Financial Results 1 January to 30 June 2025 Yrjö Wichmann CFO, Faron 14 27-AUG-2025 HALF-YEAR REPORT, JANUARY-JUNE 2025
Slide 15: Financial Results H1 2025
Financial Results H1 2025 Overview • Cash balance was EUR 13.5 million on June 30, 2025 (2024: EUR 30.0 Cost efficient million). delivery • Operating loss for the period was EUR -11.9 million (EUR -11.3 million). continued in H1 • Loss per share was EUR 0.18 (EUR 0.20) 2025 • Net assets were EUR -16
Slide 16: Financial Results H1 2025 – Financing arrangements
Financial Results H1 2025 Financing arrangements • On 5 February, Faron conducted a private placement directed to a Faron’s limited number of institutional and other investors raising financial EUR 12.0 million. The placement was oversubscribed 1.8 times. position • On 3 April, Faron entered into an
Slide 17: Faron's H1 2025 Positive clinical and financial milestones mark strong first half
Faron’s H1 2025 Positive clinical and financial milestones mark strong first half Dr. Juho Jalkanen CEO, Faron 17 27-AUG-2025 HALF-YEAR REPORT, JANUARY-JUNE 2025
Slide 18: New blood to Faron in H1/2025
New blood to Faron in H1/2025 Well-equipped to navigate the MARCH 2025 MAY 2025 complexities of Mr. Colin Bond joined the Faron Board, Mr. Ralph Hughes joined our our sector and bringing extensive international Management Team to experience from finance, CDMO and strengthen Faron's Commercial to rea
Slide 19: Significant progress with bexmarilimab's clinical trials in H1/2025
Significant progress with Strong data in bexmarilimab’s clinical trials in H1/2025 clinical trials & positive interaction FEBRUARY–MARCH 2025 APRIL 2025 JUNE 2025 with the Faron received a positive Faron announced Faron presented the FDA and EMA opinion on orphan drug positive phase II updated phase
Slide 20: Unique achievements in prestigious scientific forums
Unique achievements in prestigious scientific forums Invitations to present our data in oral sessions MAY 2025 MAY-JUNE 2025 JUNE 2025 in all three The 18th The 2025 American The 30th European international International Society of Clinical Hematology Congress on Oncology (ASCO) Association’s (EHA M
Slide 21: Strong start for H2/2025
Strong start for H2/2025 Events after the reporting period 1/2 JULY 2025 JULY 2025 AUGUST 2025 Announcing the Announcing the oral Faron announced an increase in the Recognition in acceptance of two presentation of new complete remission (CR) rate in patients bexmarilimab studies clinical and transla
Slide 22: Strong start for H2/2025
Strong start for H2/2025 Events after the reporting period 2/2 AUGUST 2025 On 8 August, Faron announced extension to its key patent family around bexmarilimab and Very positive targeting Clever-1 in cancers with a new US patent granted. This extends key patent rights around bexmarilimab from an init
Slide 23: Outlook into H2/2025
Outlook into H2/2025 Progress towards phase II/III, partnering options, and business transactions Different partnering options under consideration • Ensuring the maximizing of Faron’s shareholder value while progressing the development of bexmarilimab in both solid tumors and hematological malignanc
Slide 24: Faron's oncology pipeline
Faron’s oncology pipeline Indication(s) Regimen Phase of clinical development Anticipated Key Milestones Phase I Phase II Phase III Advanced solid tumors Bexmarilimab ▪ Completed FARON SPONSORED MATINS r/r + 1st line MDS and AML Bexmarilimab + ▪ End of phase II meeting held with the FDA FARON SPONSO
Slide 25: Q&A
Q&A Dr. Juho Jalkanen Yrjö Wichmann Dr. Petri Bono CEO, Faron CFO, Faron CMO, Faron 25 27-AUG-2025 HALF-YEAR REPORT, JANUARY-JUNE 2025
Slide 26: THANK YOU
THANK YOU 26 27-A FEUBG--22002255 HALF-YEAR REPORT, JANUARY-JUNE 2025
Faron Pharmaceuticals Oy — H1 2025 Earnings Presentation on 6ix